Basic Information
| LncRNA/CircRNA Name | EGOT |
| Synonyms | EGOT, EGO, NCRNA00190 |
| Region | GRCh38_3:4749192-4751590 |
| Ensemble | ENSG00000235947 |
| Refseq | NR_004428 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot etc. |
| Sample | cell line (HuH7, HuH7.7) |
| Expression Pattern | up-regulated |
| Function Description | EGOT depletion increases the expression of several interferon-stimulatedgenes and leads to decreased replication of HCV and SFV. Ourresults suggest that EGOT is a lncRNA induced after infection thatincreases viral replication by antagonizing the antiviral response |
| Pubmed ID | 27283940 |
| Year | 2016 |
| Title | Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication |
External Links
| Links for EGOT | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |